

DAN BURTON, INDIANA,  
CHAIRMAN

BENJAMIN A. GILMAN, NEW YORK  
CONSTANCE A. MORELLA, MARYLAND  
CHRISTOPHER SHAYS, CONNECTICUT  
ILEANA ROS-LEHTINEN, FLORIDA  
JOHN M. MCHUGH, NEW YORK  
STEPHEN HORN, CALIFORNIA  
JOHN L. MICA, FLORIDA  
THOMAS M. DAVIS, VIRGINIA  
MARK E. SOUDER, INDIANA  
JOE SCARBOROUGH, FLORIDA  
STEVEN C. LA TOURETTE, OHIO  
BOB BARR, GEORGIA  
DAN MILLER, FLORIDA  
DOUG OSE, CALIFORNIA  
RON LEWIS, KENTUCKY  
JO ANN DAVIS, VIRGINIA  
TODD RUSSELL PLATTS, PENNSYLVANIA  
DAVE WELDON, FLORIDA  
CHRIS CANNON, UTAH  
ADAM H. PUTNAM, FLORIDA  
C.L. "BUTCH" OTTER, IDAHO  
EDWARD L. SCHROCK, VA

ONE HUNDRED SEVENTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
MINORITY (202) 225-5051  
TTY (202) 225-6852

[www.house.gov/reform](http://www.house.gov/reform)

June 4, 2001

HENRY A. WAXMAN, CALIFORNIA,  
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA  
MAJOR R. OWENS, NEW YORK  
EDOLPHUS TOWNS, NEW YORK  
PAUL E. KANJORSKI, PENNSYLVANIA  
PATSY T. MINK, HAWAII  
CAROLYN B. MALONEY, NEW YORK  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA  
ELIJAH E. CUMMINGS, MARYLAND  
DENNIS J. KUCINICH, OHIO  
ROD R. BLAGOJEVICH, ILLINOIS  
DANNY K. DAVIS, ILLINOIS  
JOHN F. TIERNEY, MASSACHUSETTS  
JIM TURNER, TEXAS  
THOMAS H. ALLEN, MAINE  
JANICE D. SCHAKOWSKY, ILLINOIS  
WM. LACY CLAY, MISSOURI

BERNARD SANDERS, VERMONT,  
INDEPENDENT

Bernard A. Schwetz, D.V.M., Ph.D.  
Acting Principal Deputy Commissioner  
Food and Drug Administration  
5600 Fishers Lane, Room 1471  
Rockville, Maryland 20857

Dear Dr. Schwetz:

My office has been contacted by a woman who had to undergo a kidney transplant after taking a dietary supplement product that contained aristolochic acid. I understand that there is a known association between aristolochic acid and kidney failure. According to information on your website, a hundred people in Belgium, and several people in the United Kingdom, may have suffered some kind of renal disease as a result of taking herbal preparations that contained aristolochic acid. I am interested in knowing what steps the Food and Drug Administration (FDA) is taking to protect consumers from these potentially dangerous products.

Specifically, I would like you to answer the following questions:

1. When did FDA first become aware that aristolochic acid could cause kidney damage?
2. When did FDA first learn that dietary supplements containing aristolochic acid were being sold in the United States?
3. How many adverse event reports relating to aristolochic acid have been reported to FDA?
4. How many of these reports are of serious events?
5. How has FDA followed up on these adverse event reports?
6. What actions has FDA taken to keep these products from entering the United States, including enforcement actions against retailers and manufacturers of supplements containing aristolochic acid?

Bernard A. Schwetz, D.V.M., Ph.D.


June 4, 2001

Page 2

7. Is FDA aware whether supplement products containing aristolochic acid continue to be sold in the United States and, if so, what does FDA intend to do about these products?
8. Are these products available on the Internet?
9. Aside from a notice on your webpage, what other steps has FDA taken to alert consumers to the dangers of dietary supplements that may contain aristolochic acid?

I would like this information by June 19, 2001. If you have any questions, please call Sarah Despres of my staff at (202) 225-5420.

Sincerely,

  
Henry A. Waxman  
Ranking Minority Member

cc: The Honorable Dan Burton, Chairman  
Committee on Government Reform